Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Quarter to Quarter Aggressive Growth Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (5053)	3/10/2004 10:37:08 AM
From: Jack Hartmann	Respond to of 6930

Added RGEN at 3.30. Good move up lately. 3 Insider buys, no sells. WALTHAM, Mass., Feb. 11 /PRNewswire-FirstCall/-- Repligen Corporation (Nasdaq: RGEN - News) today reported results for the third quarter of fiscal year 2004 ended December 31, 2003. Total revenue for the quarter was $1,321,000 compared to total revenue of $2,417,000 for the third quarter of fiscal year 2003. Gross profit for the quarter was $539,000, or 41% of revenue compared to $1,276,000, or 53% of revenue for the third quarter of fiscal year 2003. Operating expenses for the third quarter of fiscal year 2004 were $2,766,000 compared to $2,182,000, for the third quarter in fiscal year 2003. The net loss for the third quarter of fiscal year 2004 was $2,127,000 or $.07 per share, compared to a net loss of $766,000 or $.03 per share for the third quarter of fiscal year 2003. Cash and investments as of December 31, 2003 were $25,659,000. Summary: Nonprofitable, but insiders buys make this biotech an interesting stock.